Medical network on April 19 - yesterday, index showed a sharp adjustment again, down to find support, disk, represented by pharmaceutical stocks significantly defensive defensive stocks, money is still with great enthusiasm. 

 

Specific view, yesterday, 136 pharmaceutical stocks outperform the market, in addition to the second new open medical and biological kappe continue word harden, slice seed Huang, beauty novartis, shin kong pharmaceutical, DE man, the company shares rose yesterday were all higher than 4%, respectively, 5.81%, 5.56%, 4.94%, 4.41%, 4.94%, lai mei pharmaceutical industry (3.54%), liuzhou medicine (3.44%), wide reputation far (3.23%), MengFaLi (3.19%), rui kang pharmaceutical (3.17%) and other stocks also. 

 

Money flows, yesterday, 128 pharmaceutical stocks shows large single net inflows, among them, ma yinglong, made by hualan bio-engineering, such as tongrentang 3 large single net inflows of the stocks in 50 million yuan of above, respectively, 59.6381 million yuan, 58.685 million yuan, 55.1326 million yuan, in addition, dahua mountain (35.7519 million yuan), baiyun mountain (35.6055 million yuan), the United States in health (34.055 million yuan), changchun high (33.4133 million yuan), hundred million sails medicine (32.8995 million yuan), wang Huang (32.7748 million yuan), east China pharmaceutical (32.0484 million yuan), will (31.1219 million yuan), and other stocks, shares big single net inflows are also more than 30 million yuan. 

 

Some analysts pointed out that in the first quarter of a-share market A prominent feature of industry leading large capitalization stocks continue to outperform small and medium-sized market value of the stock. At present although many industry leading stock valuations have historically relatively high, but from the game, incremental funds, stock supply of new ways, is expected in the second quarter of industry leading shares still has good performance. 

 

"Securities daily" market research center according to flush data statistics, as of yesterday, a total of 12 pharmaceutical shares the latest market capitalisation in 40 billion yuan of above, hengrui pharmaceutical latest tops, total market value of 129.016 billion yuan, Shanghai and sig pharmaceutical latest alex's total market value are more than 90 billion yuan, respectively, 99.852 billion yuan and 92.414 billion yuan, in addition, the latest market capitalisation in 40 billion yuan of above pharmaceutical stocks are: yunnan baiyao (89.383 billion yuan), fosun medicine (70.706 billion yuan), Shanghai pharmaceutical (59.274 billion yuan), step length (55.649 billion yuan), east China pharmaceutical (45.218 billion yuan), baiyun mountain (44.074 billion yuan), tongrentang (43.585 billion yuan), tasly (43.446 billion yuan), the company (42.655 billion yuan). 

 

Of these stocks except no agencies step pharmaceutical, 11 other stocks generally by institutions, the recent one month, tasly (15), Shanghai pharmaceutical (12), east China pharmaceutical (10) and other three stock agency favors rating number in 10 and above, hengrui pharmaceutical, fosun medicine, individual institutions, such as the company to "buy" or "overweight" rating number are also in more than five. 

 

It is worth mentioning that Shanghai alex, sig pharmaceutical, yunnan baiyao and fosun pharma stocks are generally recognized market is expected to hit one hundred billion yuan, huatai securities said bullish on sig pharmaceutical as yinpian leading companies benefit from the industry booming, hospital layout speed drive pharmaceutical trade volume, traditional Chinese medicine trade under the stimulus price rebound face upward cycle, estimated 2017, 2018 net income of 4.2 billion yuan, 4.2 billion yuan, corresponding to earnings per share 0.84 yuan, 1.02 yuan, to give 2017 p/e ratio of 25 to 30 times, highest target price to $25, for the first time to "overweight" rating. Once the sig pharmaceutical latest closing price reach agency predicted target price, the total value will exceed one hundred billion yuan to 123.681 billion yuan. 

 

And in addition to the big stock market value this feature generally endorsed, reasonable valuations, strong growth performance uncertainty has become a part of the funds in the short-term optimization pharmaceutical shares important indicators, the above by institutions of 11 large-cap stocks latest p/e ratio is below the industry average (87.53 times), Shanghai latest alex's dynamic price-earnings ratio of 61.9 times, highest performance, combined with 2016 annual report and a quarterly in 2017, the 9 of 11 companies companies have disclosed in 2016 annual report, except the tasly 2016 net profit year-on-year must decline, other companies are to realize rose, while tasly net profit year-on-year growth of 14.84% in the first quarter, the company's performance bottoming out in the future is expected to become stable growth include societe generale securities, China international capital corporation, southwest securities institutions, such as consensus.